中國富強金融(0290.HK)連續兩年收入增長超60%
格隆匯6月29日丨中國富強金融(0290.HK)發佈截至2020年3月31日的2019財年財報顯示,收入1.79億港元,相較去年同期的1.08億港元,同比增65.7%;相比於重組時2017年4988萬港幣收入,則取得了連續兩年收入增長超60%、累計增長超過2.58倍的好成績。2019財年,富強集團錄得税前虧損6218萬港元,較去年同期虧損1.03億港元,大幅減虧40%。據3月富強集團的自願公告,信達香港與PAL可換股債券已於2020年3月30日到期,集團將贖回這些到期可換股債券餘額。在此等事項完成後,集團的可轉股債券利息在新的財年或降低三分之二以上,有利於集團盈虧平衡、甚至扭虧為盈的這一歷史性時刻的加速到來。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.